Full-Time

Specialist IS Architect

Veeva Vault

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior, Expert

Hyderabad, Telangana, India

Category
Data Management
Data Engineering
Data & Analytics
Required Skills
Microsoft Azure
Python
AWS
Development Operations (DevOps)
Databricks
Requirements
  • Master’s degree with 4 - 6 years of experience in Computer Science, IT or related field OR
  • Bachelor’s degree with 6 - 8 years of experience in Computer Science, IT or related field OR
  • Diploma with 10 - 12 years of experience in Computer Science, IT or related field
  • Solid understanding of architecting and deployment strategies for Veeva Vault Platforms/Products
  • Expertise in system integration, including APIs, middleware tools, and data migration between Vault and other systems.
  • Strong knowledge of Data Lake technologies like Databricks, etc.
  • Experience in Mulesoft and Python script development
  • Extensive knowledge of enterprise architecture frameworks, technologies, and methodologies
  • Experience with system integration and IT infrastructure
  • Experience with data, change, and technology governance processes on the platform level
  • Experience working in agile methodology, including Product Teams and Product Development models
  • Proficiency in designing scalable, secure, and cost-effective solutions.
  • Have stakeholder and team management skills
  • Can lead and guide multiple teams to meet business needs and goals
  • Experience with cloud-based architectures, AWS, Azure, or similar environments.
Responsibilities
  • Develop and maintain the Amgen’s enterprise Veeva Vault Platform architecture vision and strategy, ensuring alignment with business objectives
  • Responsible for fostering platform reliability and efficiency through streamlined release management & execution, and establishing a consistent DevOps & CI/CD framework
  • Accountable for designing and building customizations & configurations on the Platform as per the business needs including creating custom objects, fields, workflows and SDKs
  • Responsible for strategizing Platform Integrations while adhering to consistent integration standards and patterns, designing integration workflows, building connectors, centralizing build & run, and driving a consistent DevOps model for integrations
  • Identify and mitigate architectural risks, ensuring that the platform is scalable, secure, and resilient
  • Maintain comprehensive documentation of the platform architecture, including principles, standards, user guides, and models
  • Drive continuous improvement in the architecture by finding opportunities for innovation and efficiency
  • Work with partners to gather and analyze requirements, ensuring that solutions meet both business and technical needs
  • Perform impact assessments, clearly define AS-IS and TO-BE states, and recommend platform upgrades following the new features and functionalities released by Veeva
  • Design platform architecture that can scale to meet growing business needs and performance demands
  • Develop and maintain logical, physical, and conceptual data models to support business needs
  • Establish and enforce data standards, governance policies, and best practices
  • Provide domain expertise in Veeva Vault to the team, offering guidance on architecture, solution design, and implementation challenges.
  • Provide hands-on technical leadership in resolving complex technical issues and ensuring smooth deployment and system integration
Desired Qualifications
  • Good Knowledge of the Global Pharmaceutical Industry
  • Understanding of GxP process
  • Strong solution design and problem-solving skills
  • Solid understanding of technology, function, or platform
  • Experience in developing differentiated and deliverable solutions
  • Ability to analyze client requirements and translate them into solutions
  • Working late hours

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.